Table 1 Pathway enrichment analysis and assessment of the statistical significance of the optimal gene set for LUAD identified by AWRMP from LUAD mutation data.

From: Adaptively Weighted and Robust Mathematical Programming for the Discovery of Driver Gene Sets in Cancers

Genes

Pathway (q-value)

CoMEt

TiMEx

KRAS, EGFR, TP53MKNK2, NF1

MAPK signalling pathway(2.00e-3)

0.02

6.45e-7

KRAS, EGFR, ABL1PAK6

ErbB signalling pathway(2.10e-3)

4.27e-8

1.57e-7

KRAS, EGFR,STK11PTEN, TP53

PI3K-Akt signalling pathway(4.70e-3)

0.05

3.34e-6

Back to article page